IL-6 Testing in Critical Care Settings: The Emerging Use of Biomarkers in Contemporary Management of COVID-19 and Respiratory Failure

January 26, 2023

Webinar Description: 

Sponsored by Bluejay Diagnostics

This sponsored webinar will discuss the challenges of identifying serious complication risks and treating patients with high-risk conditions including severe COVID-19, sepsis, and respiratory failure in emergency department and intensive care unit settings. The presenter will also discuss Bluejay's Symphony IL-6 test, which has the potential to provide simple, reliable, rapid, near-patient testing by delivering quantitative measurements of IL-6 to determine the need for additional patient care, acute intervention, and monitoring.

Target Audience

Nurses, advanced practice providers, physicians, emergency responders, pharmacists, medical technologists, respiratory therapists, physical/occupational therapists, infection prevention specialists, data/quality specialists, and more. 

Sepsis Alliance gratefully acknowledges the support provided for this webinar by Bluejay Diagnostics.

Course summary
Course opens: 
Course expires: 
Event starts: 
01/26/2023 - 11:00am PST
Event ends: 
01/26/2023 - 12:00pm PST

Mark Feinberg, MD

Associate Professor of Medicine, Harvard Medical School

Mark W. Feinberg, MD, is a cardiologist and vascular biologist at Brigham and Women’s Hospital (BWH) and an Associate Professor of Medicine at Harvard Medical School, Boston. Dr. Feinberg is Director, Program in Cardiovascular RNA Biology Research that investigates inflammatory mechanisms leading to the development of a range of macrovascular (e.g. atherosclerosis, coronary, and peripheral artery disease) and microvascular disease states (e.g. diabetes). His group has discovered non-coding RNAs and cardiovascular biomarkers, and has translated these findings into novel therapeutic approaches for ischemic cardiovascular disease. Dr. Feinberg has held various leadership roles in cardiovascular research including his service on international and national peer review study sections, editorial service, and as a Co-Chair of the Brigham Research Institute’s Cardiovascular, Diabetes, and Metabolic Disorders Center. Dr. Feinberg completed his Cardiovascular Medicine fellowship training at Brigham and Women’s Hospital, where he subsequently joined the faculty. Dr. Feinberg was inducted as a member of the American Society of Clinical Investigation and has received several major research awards including an American Heart Association Louis N. and Arnold M. Katz Prize Finalist and the David W. Haack Memorial Award.

No continuing education credits are offered for the Sponsor Innovation Webinar.

Medical Disclaimer

The information on or available through this site is intended for educational purposes only. Sepsis Alliance does not represent or guarantee that information on or available through this site is applicable to any specific patient’s care or treatment. The educational content on or available through this site does not constitute medical advice from a physician and is not to be used as a substitute for treatment or advice from a practicing physician or other healthcare provider. Sepsis Alliance recommends users consult their physician or healthcare provider regarding any questions about whether the information on or available through this site might apply to their individual treatment or care.

Please login or register to take this course.

To register for this webinar, please follow these steps:

  1. If you have a Sepsis Alliance Institute account, select Login. If you do not yet have an account, select Register to create your FREE account. 
  2. Select Take Course, then select Take Course again.
  3. Click Start under the Webinar (Via Zoom) tab in the course outline to complete your registration. You MUST do this step to receive your Zoom join link.
  4. When it is time to join the webinar, select Webinar (Via Zoom). Select Join the webinar. The Zoom window will pop up and you will see the webinar as you normally would. 

Please don't hesitate to reach out to us at with any questions.